Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data

The potential new oral treatment showed a reduction in lung function decline

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Impetus Digital

- PMLiVE

Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

- PMLiVE

Boehringer Ingelheim to boost antibody discovery with partner Twist

The biotech company will use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets

- PMLiVE

CureVac to push ahead with first- and second-generation COVID-19 vaccines

The biotech will seek EMA approval for first-generation jab while trials are due to start for second-generation jabs in Q4

- PMLiVE

Numbers, navigation, and narratives: digital storytelling in medical communications

Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...

Avalere Health

- PMLiVE

Boehringer Ingelheim, Lifebit to use AI to detect infectious disease outbreaks

Partnership will utilise real-world data for the early reporting of global outbreaks

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

Therapeutic VR for Managing Pain & Improving Patient Outcomes

Ramsay Brown, CEO and Founder of Quol, delves into several different HealthTech topics, including the concept of VR therapeutics and the importance of incorporating behavioral science and neuroscience into VR solutions, as...

Impetus Digital

- PMLiVE

Boehringer/Lilly’s Jardiance hits the mark in pivotal heart failure trial

Drug reduced risk of death/hospitalisation in patients with and without diabetes

Forging innovative solutions by merging art and science

In the latest episode of Impetus Digital's Fireside Chat, we dive into the concept of merging art and science with Ariel Garten, Founder & Chief Evangelism Officer at Muse. Ariel...

Impetus Digital

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links